Skip to main content
. 2021 Feb 25;13(5):957. doi: 10.3390/cancers13050957

Figure 2.

Figure 2

B. bre JCM92 boosts oxaliplatin efficacy by enhancing anti-tumor immunity in the spleen. (A,B) Immune cell profiling of the spleen in mice treated with oxaliplatin in combination with B. bre JCM92 (A) or B. bre Bb03 (B) using flow cytometry analysis. Data are expressed as the means ± SEM. p-values were determined by one-way ANOVA using Tukey’s post-test. * p < 0.05, ** p < 0.001, *** p < 0.001, and ns, not significant.